• Explore /
  • Poster
  • / TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.

TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.

Abstract Poster

Authors

null

Lucia Nogova

Lung Cancer Group Cologne, Center for Integrated Oncology, University Hospital Cologne, Cologne, Germany

Lucia Nogova , Masyar Gardizi , Marc Christiaan Allardt Bos , Matthias Scheffler , Christian Mattonet , Lukas Carl Heukamp , Hans-Ulrich Schildhaus , Uwe Fuhr , Wilfried Eberhardt , Henning Reis , Marcel Wiesweg , Kurt Werner Schmid , Gernot Schoch , Yon-Dschun Ko , Monika Heidi Serke , Martin H. Schuler , Reinhard Buettner , Juergen Wolf

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer - Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

DRKS00003301

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 8109)

DOI

10.1200/jco.2014.32.15_suppl.8109

Abstract #

8109

Poster Bd #

290

Abstract Disclosures

Similar Posters

First Author: Zandong Yang

First Author: Julien Mazières

First Author: Wenfeng Fang

First Author: Evan Y. Yu